|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
FEBRUARY 20, 2006
Fast Growth At Illumina Is In The Genes  Illumina (ILMN
) has become a rising star in the complex analysis of gene variation, and the stock shows it. Since early January the shares have risen some 50%, to 21. The company develops research tools for genotyping and gene expression, which provide information to improve drugs and other therapies. The tools help Big Pharma and academic labs process the billions of tests necessary to convert raw genetic data into medically valuable info, not only to improve drugs but also to customize diagnoses and treatment, says Jeffrey Loo of Standard & Poor's (MHP
). He sees a 60% jump in Illumina's 2006 sales, to $118 million, up from 2005's $73 million. Understanding genetic changes is critical to developing personalized medicine, says Loo. Illumina is one of five U.S. players in a global project to create a map of genetic variations for disease-related research. Genotyping, the fastest-growing sector of gene analysis, is where "we are winning more customers than our rivals," says Illumina CEO Jay Flatley. According to John Sullivan of Leerink Swann, who rates the stock "outperform," Illumina's new product, 500K BeadChip, to be launched this year, will make the company more competitive with DNA chip technology leader Affymetrix (AFFX
).
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2006, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version